Latest / Adventures Through The Mind / Treating Traumatic Brain Injury with Ibogaine | Dr. Nolan Williams ~ ATTMind 188
Transcript
- 0:00Hello everyone and welcome back to Adventures Through the Mind.
- 0:04This is a podcast that explores topics relevant and related to
- 0:07psychedelic culture, medicine, and research. I'm your host, as
- 0:12always, James W. Jesso. This episode is going to explore
- 0:17some of the groundbreaking research that has come out
- 0:20recently around the use of the psychedelic compound
- 0:24ibogaine in the treatment of mild traumatic brain injury,
- 0:28also called concussions. Our guest is Dr. Nolan Williams.
- 0:36[Music]
- 1:04Nolan Williams, MD, is an associate professor within the
- 1:08Department of Psychiatry and Behavioral Science and
- 1:11director of the Stanford Brain Stimulation Lab. He has a broad
- 1:15background in clinical neuroscience and is triple
- 1:18board certified in general neurology, general psychiatry,
- 1:22and behavioral neurology, and neuropsychiatry. Themes of Dr.
- 1:27Nolan's work include examining the use of spaced learning
- 1:30theory in the application of neurostimulation techniques,
- 1:34development, and mechanistic understanding of rapid acting,
- 1:38antidepressants, and identifying objective biomarkers that
- 1:43predict neural modulation responses in treatment-resistant
- 1:46neuropsychiatric conditions. His work resulted in an FDA
- 1:51clearance for the world's first non-evasive rapid acting
- 1:55neuromodulation approach for treatment-resistant depression.
- 2:00He has published papers in high-impact peer-reviewed
- 2:03journals including Nature Medicine, Nature Mental Health,
- 2:06Brain, American Journal of Psychiatry, and the Proceedings
- 2:09of the National Academy of Science. Further, Dr. Williams
- 2:13also has an expertise in psychedelic medicines for
- 2:17neuropsychiatric illnesses and is the first investigator to
- 2:20conduct mechanistic clinical trials exploring the
- 2:24neurobiological effects of ibogaine. Specific to that last
- 2:28point, Dr. Williams was the head of a study run at the
- 2:31AmbioLife Sciences Center in Mexico where he evaluated the
- 2:35effects of ibogaine on veterans with brain injury, particularly
- 2:39mild traumatic brain injury also called concussion. The first
- 2:44paper released from these results is titled Magnesium
- 2:49Ibogaine Therapy in Veterans with Traumatic Brain Injuries
- 2:53and was published in the journal Nature in 2024. He joins
- 2:57us on the show today to talk about brain injuries, generally
- 3:02ibogaine, and the treatment of brain injuries with
- 3:05ibogaine. We also talk about ibogaine as an anaerogen, the
- 3:10cardiac risks of ibogaine, and how to mitigate them, how
- 3:15ibogaine compares to other treatment methods for brain
- 3:18injuries, including other psychedelic molecules,
- 3:21microdosing ibogaine for traumatic brain injury,
- 3:25and that ibogaine can seemingly de-age the brain.
- 3:29Additionally, we also talk about pharmacology versus context in
- 3:34the healing benefits of psychedelics, separating high
- 3:37technology from time, and how and why using the vehicle of
- 3:43capitalism to fund psychedelic research may be a good thing.
- 3:48Okay, so that's the interview you're about to hear before we
- 3:51get into it. Two things. Number one, this interview isn't two
- 3:54parts. It's one episode, but it's two parts. I had to get on
- 3:58two separate calls with Dr. Williams in order to get the
- 4:01entirety of this interview, and you'll notice the bandwidth isn't
- 4:05super great in the first one, but it's quite clear in the second
- 4:08one. You might not notice a difference at all, but if you're
- 4:11watching the video feed, you'll definitely notice a difference, so
- 4:13a bit of a heads up there. The second thing is that this podcast is
- 4:17brought to you by listeners like yourself via Patreon.
- 4:21If it wasn't for my patrons on Patreon and their ongoing
- 4:25continuous contributions to the production of the show and the
- 4:28various costs, time-wise and material-wise, in its
- 4:33production, I wouldn't be able to do it, and I love doing this, and I
- 4:37love the larger body of work that supports it.
- 4:40So, thank you patrons. An extra thank you goes to those who have been
- 4:44giving quite significantly, and in doing so, their names are
- 4:48presented on the screen here on YouTube or in the description to
- 4:50this episode, wherever you are checking it out. So, thank you
- 4:53very much to them. If you are finding value in the show,
- 4:57and you're not yet a patron, you're not yet financially
- 5:01contributing to the production of the show, I ask you to please
- 5:04consider becoming my patron on Patreon. You can do so for as
- 5:07little as $2 a month, and everything is something, and it all
- 5:12adds up into the possibility for me to do this thing that I so
- 5:16deeply care about as my full-time job and get paid a
- 5:19full-time wage to do it. You can head to patreon.com/jameswjesso
- 5:24or follow the link in the description to this episode in
- 5:27order to check out becoming a patron. You can't afford to
- 5:31become a patron right now, but you'd like to stay up to date
- 5:33with what I'm putting out on Patreon. You can always become a
- 5:36free member, and I encourage you to do so, and thank you in
- 5:39advance. Without much further ado, here is my interview with
- 5:43Dr. Nolan Williams on Adventures Through the Mind,
- 5:45episode 188, Treating Traumatic Brain Injury with Ibogaine.
- 5:50Enjoy. Dr. Nolan Williams, welcome to Adventures Through
- 5:54the Mind. Yeah, thanks for having me. Appreciate it.
- 5:59I am interested and excited for this interview because, I mean,
- 6:05psychedelics generally, psychedelic medicine is a topic
- 6:08that I'm very curious about, have a lot of excitement for.
- 6:11Sometimes I've got an edge for the movement of the culture, but
- 6:13that's an aside. But, specifically, the excitement is
- 6:21pertaining to where this particular psychedelic medicine
- 6:25or what it's treating, which is essentially traumatic brain
- 6:28injury. And what makes me excited about that is that I
- 6:32found out that you were doing this research. She's from a
- 6:36friend of mine and also a colleague for many years, Trevor
- 6:42Miller, who works at Ambio, which is the same center that
- 6:45you did the research we're going to be talking about today at.
- 6:50And I've also known Jonathan Dickinson for quite a while as
- 6:52well, one of the other members of Ambio. In fact, he was, I
- 6:56think, the third person I ever had on this show, which is back
- 7:00several years ago. And I got a message from Trevor
- 7:04explicitly telling me about this research because he had
- 7:06learned that I had incurred a head injury from a car
- 7:10accident now a little over two years ago. And he was like,
- 7:14"Hey, you might find this personally interesting and
- 7:17professionally interesting." And I was like, "You know what,
- 7:20Trevor? You are absolutely correct. Fast forward some amount
- 7:25of time. Your paper has been released and here we are talking
- 7:30about it." So the paper is about the efficacy of using Ibogaine
- 7:36in a combination with magnesium in a structured setting, that
- 7:42structure being Ambio's sort of clinic or center there and the
- 7:47effects that it had on veterans that had traumatic brain
- 7:52injuries. Now, I want to explore that piece by piece throughout
- 7:56the course of the interview and starting with specifically,
- 7:59maybe seems like an obvious question, but it's quite a
- 8:03complex question, which is what is a traumatic brain injury?
- 8:08And you could tackle this and/or the causes, symptoms, prevalent
- 8:14impact on persons in society, however you want to tackle the
- 8:16question. Yeah, that's a good question. So whenever the head
- 8:22gets accelerated and kind of immediately stops, what happens
- 8:31is that the components that had the brain, the skull, all that
- 8:36stuff, the cerebral spinal fluid decelerates at different
- 8:40speeds, and the brain decelerates slower than the skull.
- 8:49And what that does essentially is it allows for the brain to
- 8:54impact the skull and effectively hit the skull. And that's
- 8:59what you see, whether it be football, TBI, or even a blast
- 9:05injury or whatever, that the brain moves in a different way
- 9:08than the skull moves, since the brain effectively hits a part of
- 9:14the skull and causes injury to the brain, because obviously the
- 9:17brain is less hard and less dense than the skull. And so
- 9:24there are kind of standard ways in which that happens. And
- 9:30that's kind of the frame that this kind of falls under.
- 9:37So in the case of military TBI, a lot of it ends up being blast
- 9:40injuries and whatnot, where people get thrown back and their
- 9:43brain actually accelerates quite quicker than their skull.
- 9:46Their brain effectively smashes into a part of the skull and
- 9:49causes a dysfunction. And that can produce a whole host of
- 9:55symptoms that for some people persist ongoing.
- 9:59Can you give us a sense? I guess any kind of injury can
- 10:04take a number of forms. If I think about injuring my knee,
- 10:10I could tweak it a little bit and it hurts for a little while
- 10:14and I cause minor damage, but it's whatever. Or I could have a
- 10:19minor strain or I could fully tear my ACL. I could shatter my
- 10:25part of the bone or something. There's like a wide range of
- 10:29potential injuries that can occur when I say fall on my
- 10:33knee. What's the sort of range for the kind of what will
- 10:39qualify as a traumatic brain injury? You don't have to go
- 10:43into every single one, but at its least extreme, it might be
- 10:46like this. At its most extreme, what has happened to the brain
- 10:50would be diagnosed as this. Just give us a sense of the range.
- 10:56Yeah, I mean, so there's mild, moderate, and severe traumatic
- 10:59brain injury. Severe traumatic brain injury is seen on
- 11:02structural MRI. It usually takes the form of a kind of a
- 11:08traumatic subarachnoid hemorrhage or a contusion of
- 11:10the brain. So basically there's some bruising bleeding that
- 11:14happens alongside structural injury. You can have people get
- 11:19in car accidents and they can have the orbit fracture backwards
- 11:24and hit the orbitofrontal cortex and cause contusions and whatnot.
- 11:29So that's all kind of within the range of possible kind of severe
- 11:35TBI, whereas mild range of what we think about as a concussion,
- 11:39really, there's nothing on brain MRI. There's nothing on CT,
- 11:42standard MRI and structural MRI and CT. So you're really just
- 11:46seeing a kind of functional impairment and then a headache,
- 11:49nausea, vomiting, that sort of thing. And so there's a big range
- 11:53of what you can experience from the severity. And then because
- 11:58the brain has different functions in the place in which
- 12:02the brain accelerates and hits has a different function,
- 12:05you can have a host of symptomatology that presents
- 12:09as a result of where on the head you were hit or which
- 12:15direction the blast injury happened.
- 12:17Yeah, like say theoretically, I could hit my head in a part
- 12:24that is like that area of the brain is more involved with,
- 12:28say, emotional regulation or I could have the trauma happen
- 12:32somewhere that's more involved in sort of like neuro-optical
- 12:37function. So on one end, I could have a lot of emotional
- 12:40dysregulation, on another end, it might present as like
- 12:43difficulties and sort of like managing my I function. Is that
- 12:46kind of what you're speaking to?
- 12:47Yeah, yeah. So it's anatomically specific, as is everything with
- 12:53the brain, right? If you have a stroke in one region, you have
- 12:56one set of symptoms, you have a stroke in another region, you
- 12:58have another set of symptoms, you have a, you know, whatever
- 13:03other, you have a seizure in one part of the brain, you're gonna
- 13:05have a set of symptoms, you have a seizure in another part of
- 13:07the brain, you have a different set of symptoms. So that's the
- 13:10complexity of the heart is that the trauma inflicted has a
- 13:15gradation of severity, as well as a location specific
- 13:21symptomatology that coincides. So that's the, does it make
- 13:25sense?
- 13:26Yeah. And so like TBI as a term refers to like a possibly quite
- 13:31a huge range of both sort of like, what's injured, how it's
- 13:36injured, and are like what part of the brain, but like what's
- 13:39injured, how it's injured, the severity of that injury, and it's
- 13:43sort of like, its symptom expression.
- 13:46Yeah.
- 13:48And I'm wondering what, like, if you could give us a sense of
- 13:53what the impact that would have on a person and then maybe
- 13:57expand that out into society as well. Because, you know, even
- 14:01if you said, you know, they could have headaches or, you
- 14:04know, dizziness, etc. But there's a whole range of other
- 14:08symptoms that people with head injuries tend to have going all
- 14:11the way into increased sort of anxiety symptoms that present
- 14:15as post traumatic stress disorder, depression, like
- 14:18ongoing sort of like energy, crisis, these kinds of things.
- 14:23What would you describe as the sort of impact a head injury
- 14:29could have on a person's life?
- 14:31Yeah.
- 14:33So, you know, any neuro dysfunction, whether it be head
- 14:40injury or stroke or whatever it is, can have profound impact
- 14:45on quality of life and ability to perform activities of daily
- 14:49living, right? Those are the two things that people think about
- 14:52as a kind of general metric that's not neuro atomically
- 14:56specific, right? You know, my ability to get everything done
- 15:00I need to get done my ability to be happy with my own life,
- 15:05right? And traumatic brain injury symptoms that are
- 15:09chronic affect both of those things, right? They reduce your
- 15:13quality of life and they increase they reduce the, you
- 15:18know, the amount of activities of daily living that you can be
- 15:21involved in, that you can perform yourself, right? And, you
- 15:27know, that's a huge personal cost and it's a huge societal
- 15:34cost, right? The personal cost is the personal cost is that,
- 15:41you know, quality of life years are reduced, you know, so it's
- 15:46not just, you know, you can think about the number of years
- 15:49you live, you can also think about the number of years that
- 15:52you live well, right? And you want, from my vantage point, you
- 16:00want to live a long life and you want to live a healthy life,
- 16:08right? If not all of it, right? And traumatic brain injury, you
- 16:13know, at minimum reduces for some people the number of
- 16:18quality years they have. And then depending upon the
- 16:22interaction between that and other factors, it can even
- 16:24reduce, you know, lifespan, you know, if it's associated with
- 16:30other medical comorbidities. And so I think, I think that coming
- 16:35up with ways of reversing disability related to anything,
- 16:40including traumatic brain injury is super important. I think that
- 16:45the promise of neuroplasticity psychedelics are the ability to
- 16:59potentially have a restorative effect beyond just a symptomatic
- 17:01improvement. Symptomatic improvement is great.
- 17:03Restoration, neuro-restoration is the name of the game, right? If
- 17:07you can restore function to pre-morbid levels, that's super
- 17:12important. And just to clarify, because you cut out there for a
- 17:16second, you were, you had said that the potentials of like
- 17:23neuroplastic effects of psychedelics can have like
- 17:26long standing positive effects on like brain injury, not just in
- 17:30reducing symptoms, but even just like bringing back a more sort
- 17:33of like functional brain. Is that what you're saying there?
- 17:39Yeah, I mean, in the like, kind of sci-fi range of the
- 17:44possibilities of what this is doing, right, if you can, you
- 17:49know, if you can restore function to pre-morbid levels by
- 17:53having a neurotrophic effect, having an effect where you're
- 17:58effectively, at least in kind of mild cases, as we saw in this
- 18:02study, like, seemingly restoring function, you know, restoring
- 18:06function is different than symptomatically improving
- 18:08something, right? I can have heart failure and have a terrible
- 18:12heart and give drugs that restore my heart's ability to
- 18:18might that can, can reduce the symptoms of congestive heart
- 18:22failure, such that while my heart's the same, I'm not having
- 18:26shortness of breath and water in my lungs and stuff like that.
- 18:29But my heart's the still the same, right? If you do an
- 18:32echocardiogram, that drug really hasn't, in some cases, hasn't
- 18:36changed the nature of my heart. It's just like, change the
- 18:40physiology such that like my bad heart works okay, you know, for
- 18:46symptom, you know, symptomatically. That's very
- 18:48different than saying, you know, I've got a drug that can
- 18:52effectively reverse congestive heart failure, we don't have
- 18:55drugs that can totally reverse congestive heart failure to a
- 18:59point where people don't meet criteria for congestive heart
- 19:01failure, right? And so even in the heart, which we know a lot
- 19:05more about, we don't have like, completely restorative
- 19:11technologies. So the idea that, again, and they're kind of, I
- 19:15don't, we don't totally know, right, but in the kind of sci-fi
- 19:17range of what this could do, you know, and what, you know, some
- 19:22people are hoping it can do, we have a lot more work to do to
- 19:26figure out if that's true, is that you could have some
- 19:29restorative function, right? You're bringing the brain back
- 19:31to some place that it was at pre injury. And that's the part
- 19:37that I don't know, but it seems to me like, if there is a drug
- 19:44that could do it right now, that Ibogaine has, you know, is one of
- 19:49the best candidates for that, given what we've seen. But we
- 19:53just don't know, we have a lot more work to do to really figure
- 19:56that out.
- 19:57I want to dive specifically into Ibogaine, and then the results
- 20:02that you got out of your study in a minute. But I think I want
- 20:06to really like double down for listeners who, like even myself
- 20:13as somebody who is still in the sort of long running effects of
- 20:17what, you know, post concussion syndrome, the amount of sort of
- 20:23misunderstanding I had about the, about the condition and
- 20:27about its impact and the amount of misunderstanding and
- 20:29misperception that the sort of like, larger society has on on
- 20:35how this would impact a person, I want to kind of like, really
- 20:38help accentuate that. It's I've heard it described oftentimes
- 20:44as like an invisible injury. Like if you see somebody walking
- 20:48on crutches, you know, right away, oh, they have some sort
- 20:50of, you know, orthopedic condition that means that they
- 20:53need to rely on this thing to walk. But you don't generally
- 20:57see and be like, Oh, that person has a brain injury, you just
- 21:02perceive their behavior, or they're sort of, you perceive
- 21:07their behavior in a particular way, and not recognizing that
- 21:09sometimes both as a consequence of the symptom, and as a direct
- 21:13symptom, their ability to function cognitively,
- 21:17emotionally, relationally, socially has all been
- 21:21compromised to a point that makes it extremely difficult
- 21:24and sometimes problematic for not just the person, but their
- 21:27relationships. For example, from what I understand, there's a not
- 21:33insignificant sort of observation that emotional
- 21:36destabilization and of course, from that problems in relating
- 21:41even as far as like intimate partner violence could be a
- 21:45direct consequence of changes that happen to the brain from
- 21:49brain injury or repeated concussions. I think I just
- 21:54want to make that clear for listeners by saying it. But if
- 21:56you'd like to comment or sort of like expand on any that I
- 22:01welcome you to do so.
- 22:02I mean, there's, you know, there's a huge, like I said,
- 22:13it's much more about the neuroanatomy and the severity
- 22:16than it is like that it's TBI per se, right? You have the same
- 22:19symptoms of somebody has a stroke in the same region, right?
- 22:21It's not a, it's not like, hyper specific to TBI. The problem
- 22:26with TBI and constructing therapeutics for TBI is that
- 22:30there's no symptom, there's no good symptom scale, right? If
- 22:34you have a visual cortex hit, you're going to have a very
- 22:39different set of symptoms. And if you have a prefrontal cortex
- 22:42hit, or primary auditory cortex, or whatever it is, right, like
- 22:46there's, there's just like a whole host of potential
- 22:49symptomatology that aligns much more with the anatomy than it in
- 22:54the severity than it does the specifics of TBI per se, but the
- 22:59idea that brain injured persistent brain injuries can
- 23:04manifest in a huge range of symptomatology makes sense
- 23:08because the brain can manifest its behavior in a whole huge
- 23:11host of potential behaviors that you see for people walking
- 23:15around in the streets today, you know, and so it just falls
- 23:20within that same big range.
- 23:22I want to before I specifically move on to Ibogaine, this is the
- 23:26last question I have about TBI specifically, which is, you know,
- 23:30you spoke to like the huge implications this could have on
- 23:35compromising someone's quality of life and ability to function
- 23:38in life. I'm wondering what kind of metrics there are with
- 23:44respect to the amount of TBI that is happening broad scale, say
- 23:50in the United States, I believe that's where you're located. And
- 23:55what the sort of proposed impact of this sort of amount of TBI is
- 24:00is having on society as a whole, as we understand like the
- 24:03necessities of a person's function within our socio
- 24:07economic system.
- 24:11Yeah, I mean, that's probably pretty hard to quantify just
- 24:15because, you know, we don't even know, a lot of people have had
- 24:21at least a concussion at some point, right? And we don't even
- 24:24know the the, the scale of that the implications of that, it's
- 24:30probably super under diagnosed, because a lot of people just
- 24:33shake it off. You know, are there persistent symptomatology
- 24:37related to that? It is some of the risk of what we think about
- 24:40as idiopathic psychiatric illness. So the things that we
- 24:44think are just spontaneous or happen as a result of like,
- 24:48stress within one's life, how much of that is actually
- 24:52post traumatic mild traumatic brain injury, we just don't even
- 24:55register that, right? So I think the question is a good one. The
- 24:59answer is completely unclear, you know, it's it's seemingly very
- 25:03broad. You know, from from what you can kind of read in the tea
- 25:08leaves of how many people have had a concussion in their life,
- 25:12you know, and how many of those percentage of those people have
- 25:15had, you know, a subsequent psychiatric illness, you know,
- 25:19it could be a fair amount of those that at least that was a
- 25:22risk factor for but we don't we don't really we don't really
- 25:27know, you know, I think what we do know is the folks that have
- 25:31had a reasonably pretty least reasonably significant, let's
- 25:37say sports related concussion that everybody on the field
- 25:42visit, you know, can kind of visualize as it happens, or
- 25:46people that are in blast injuries in the military that
- 25:49have some set of symptomatology that their fellow military kind
- 25:54of acknowledge is a change. But you know, even with, you know,
- 26:01the sort of thing, the were, were folks have, you know,
- 26:08ex football players or boxers or whatever, like 20 years later,
- 26:11start having these cognitive problems. Even in some of those
- 26:14cases, it's not a direct head injury, right? It's, it's
- 26:18repeated body injury, like body pressure injuries where people
- 26:23get hit in their stomach, and then there's a force transmitted
- 26:26up to the head, for instance, right, and there's repeated
- 26:30body hits that happen over and over again. And that seems to
- 26:33have a negative, you know, negative impact on the brain,
- 26:37because you're transmitting high amounts of force up to the
- 26:39head, you know, we just don't, we don't have a good handle on
- 26:44this, because none of it's being measured. You know, nobody's
- 26:48really going around and kind of measuring other than some of
- 26:51these, like football helmets that people have made and that
- 26:54sort of thing. But, you know, there's probably there's, there's a
- 26:58paucity of kind of brain measurements at, you know, at
- 27:05large in society that can answer that question. I hope in 20
- 27:09years, we, we, we have metrics and measurements that are
- 27:12continuous measurements that can tell us some of this.
- 27:15But from your, if you were to, if you were to make a sort of
- 27:19educated guess from the data that you do have, you do feel
- 27:23like it would be fair to say whatever that effect is, it's
- 27:26likely substantial?
- 27:27Yeah, I think so. I mean, it's, you know, anything that crosses
- 27:34the 1% mark in culture and society has a huge impact,
- 27:38right? I mean, we know that, you know, and so just by the scale
- 27:44of things. And so in that way, absolutely.
- 27:47So let's move in directly into Ibogaine. So I kind of wanted to
- 27:52structure it like, okay, this is traumatic brain injury, that's
- 27:54its own little island, you know, this is Ibogaine, that's its own
- 27:56little island. Now let's, you know, explore the waters around
- 28:00these two things where that where they sort of meet in the in
- 28:03the tidal flow. So with that, what what is Ibogaine? Can you
- 28:08give me a little sense of what this molecule is and how it
- 28:13affects the brain?
- 28:16Yeah, it's a it's an alkaloid of the the Iboga root bark, which
- 28:25is the Iboga tree is a central West African tree. The root bark
- 28:32is contains a host of alkaloids, including Ibogaine. But there
- 28:37are others, Ibogalein, Ibogamine, you know, on and on.
- 28:41So it's not the only alkaloid. The buliti have used Iboga root
- 28:48bark ceremonially for for millennia. The French discovered
- 28:55this in 1899. And by 1930, isolated Ibogaine and turned it
- 28:59into a drug that was used in France until 1966. Then that
- 29:04went on the Controlled Substances Act in France. And, you know,
- 29:08as a Controlled Substance Act in the US and other places that
- 29:11that limited use of these these compounds. Every country, not
- 29:20Canada, not Mexico, not Australia, not New Zealand. And
- 29:23so Ibogaine is kind of unique in the sense that it didn't get
- 29:26kind of worldwide band, it got banned in certain places. And,
- 29:31you know, it's been used kind of in these underground clinics
- 29:35since the 70s to try to treat folks with with a variety of
- 29:43symptomatology, but primarily in the addiction range, you know,
- 29:46and the kind of opiate use disorder and related addictions
- 29:50in it. For some reasons, we understand for some reasons, we
- 29:54don't seems to interrupt addiction. And then, you know,
- 29:58much more recently, there's, there's been an interest in in
- 30:03utilizing this as a neuroplastic agent to try to treat people
- 30:07with brain injury, as you noted earlier.
- 30:10What do we know about about the direct pharmacological effects
- 30:18of Ibogaine unrelated to, you know, treating a particular
- 30:22condition or disability or injury? What do we know about
- 30:26just broad scale Ibogaine goes in, this seems to happen in the
- 30:30brain? Yeah. So it upregulates neurotrophic factors like glial
- 30:37derived neurotrophic factor, brain derived neurotrophic
- 30:40factor, and produces, you know, a whole host of interactions with
- 30:47the serotonin receptor with with the opioid receptors with
- 30:52glutamate receptors. And so it works kind of like ketamine, it
- 30:56works kind of like MDMA, it works kind of like classic
- 30:59psychedelics, it has this really broad effect. And the kind of
- 31:02synthesis of all that is that it produces this very stereotype
- 31:06psychological phenomenon in which people have a earlier life
- 31:12reevaluation of memories that primarily were emotionally
- 31:18salient. And for a lot of people end up being traumatic in which
- 31:21they reevaluate the memory in a neutral third party stance, and
- 31:25they're able to re contextualize it and then seemingly reintegrate
- 31:31the new context into their memory system such that the
- 31:36traumatic aspects of it change and people have a better
- 31:41understanding of what it is. And so that's, that's the, you know,
- 31:45that's the drug both phenomenologically and
- 31:47pharmacology pharmacologically.
- 31:51Now I, I did, you did refer to it as a psychedelic, I understand
- 31:57that to be a very fair characterization, although, and
- 32:00you'll have to forgive me if I'm kind of like confusing this
- 32:03because I read a couple of papers on the effect of ibogaine
- 32:06including including yours to prepare for this interview. So
- 32:10it might not have been used specifically. But the
- 32:12referencing ibogaine, not just as a psychedelic, but also as an
- 32:16onyrogen, which is like a substance or chemical that
- 32:22generates dreams or dreamlike states. Can you just let me know
- 32:27if I'm just like misattributing that to you? But if so, can you
- 32:29outline a little bit why it would sort of fit as an
- 32:33onyrogen as well as a psychedelic in contrast to say,
- 32:36no one's calling psilocybin an onyrogen?
- 32:39Yeah, so the reason why people think about as an onyrogen is
- 32:44that it produces a dreamlike phenomenon in which that
- 32:48reevaluation occurs, right? And it's all like, you know,
- 32:53primarily closed eye reevaluation, it's not an open
- 32:56eye, kind of visual distortion, visual, you know, hallucination,
- 32:59visual, perceptual change that happens with say, LSD or
- 33:04psilocybin, right? And so, you know, it's these things are
- 33:11imperfect, right? You know, the psychedelic terminology you
- 33:18talk to, a really strict folks who have this kind of very
- 33:24a psychedelic, a receptor agonist in order for them to
- 33:32accept it as a psychedelic and only classic psychedelics like
- 33:35psilocybin else to really fit into that bucket, you know, and
- 33:40then that's kind of the splitters and the lumpers will
- 33:42think about ketamine, even in MDMA is psychedelics, and the
- 33:48splitters are going to say that, you know, that's the ketamine
- 33:51is a dissociative anesthetic and MDMA is an intactogen or an
- 33:56empathogen, right? So it's, these are splitter, lumper
- 34:01problems, it's not really like, you know, and so, you know, you
- 34:05can call it an erogen, I think it's totally fair to call it a
- 34:07psychedelic in the paper, we call it an atypical psychedelic.
- 34:10I think the nice thing about referring to it as an erogen,
- 34:15which is how we primarily referred to it in the paper is,
- 34:18you know, there's there's baggage on LSD, you know, and
- 34:23that baggage is going to stick around for a while until the
- 34:26boomers are, you know, until it's 2060 or something, you know,
- 34:30to be in and so it's one of these things where, you know,
- 34:33from from that standpoint, you know, there's there's some
- 34:38baggage around the term psychedelic, there's some baggage
- 34:42around some of the psychedelics, that's going to take some time
- 34:45to shake, I think. The nice thing about Ibogaine as a
- 34:49therapeutic agent is that Ibogaine does it is not, you
- 34:56know, is not a recreational substance in any form or
- 35:00fashion, right? You can make an argument and a pretty strong
- 35:02one that MDMA can be a therapeutic MDMA can be a
- 35:05recreational substance, you know, as we all know, right,
- 35:08people were using MDMA and raves, they probably continue to do
- 35:11so, you know, we're going to see an FDA approval for this
- 35:15hopefully, in the summer, you know, I don't think that that's
- 35:20the that's going to be a fair characterization of Ibogaine at
- 35:23all, right? It's not recreational, people don't
- 35:26particularly enjoy it, for the most part. And, and because of
- 35:31that, it's not, you know, it's not something that I think we're
- 35:35going to have as much of an abuse liability risk on. And in
- 35:39fact, like people, you know, the stories of Howard Lotsoff and
- 35:42others were, they ordered this because they wanted to have a
- 35:49therapeutic, a recreational effect when nobody knew what it
- 35:52would really do. And they had a therapeutic effect, but not a
- 35:55recreational one, right? And a lot of what you hear about with
- 35:59Ibogaine too, is that people are not, if you, if somebody takes
- 36:05Ibogaine, you have a conversation with me, so it
- 36:07really helped me, I was like, Oh, when are you gonna do it
- 36:09again? Like, I don't know. I'm not really sure. I'm gonna do
- 36:12that again. You know, I don't know if I'm gonna go through
- 36:15that again. You know, and so it's one of these things where,
- 36:19you know, and that's not everybody, you know, I'm sure
- 36:21Trevor and Jonathan have some friends or whatnot that that
- 36:25I've done it multiple times, but as a generality, it's not, it's
- 36:30not something that like people are like jumping to do the next
- 36:33week, right? You got to be really intentional about it. And
- 36:36it's not a frequent use thing. So it doesn't really fall into
- 36:41the abuse liability tolerance kind of story. Whereas ketamine
- 36:46certainly does, you know, and some, for some folks, you know,
- 36:50MDMA does, you know, and then I think like the classic
- 36:54psychedelics, it's more, more in the middle, right? People will
- 36:59take those a burning man or whatever people will not take
- 37:03them in a, you know, an abuse liability sort of way,
- 37:06generally, so it's kind of pretty low risk, but but also,
- 37:10you know, reasonably recreational.
- 37:12Yeah, it's exciting to see the sort of, you know, medical
- 37:18potential or like just even the research potential of ibogaine
- 37:21because of what you just described there with a kind of
- 37:24like not necessarily having that same baggage and not necessarily
- 37:28having that same abuse liability, sort of potential. And also
- 37:34to its, its, its regulatory status makes my assumption is it
- 37:39makes it perhaps easier to do research on it than it would if
- 37:43it had no.
- 37:45No, and that's because of the cardiac risk, right? And so it's
- 37:49probably the hardest to get through the FDA, because of the
- 37:53risk of having an arrhythmia, but it's not really the
- 37:56psychedelic effects as much as it is the cardiac risk and it's
- 38:00kind of long tail of drug, you know, in system, you know, it
- 38:06lasts for a while. And so that's really the issue from
- 38:10regulatory standpoint is that there's been deaths, right?
- 38:13Primarily in people with opiate use disorder and addiction and
- 38:17whatnot. But even in the absence of that, there have been, you
- 38:21know, a couple of cases of people that didn't have that. And so
- 38:26studying this is very hard. You know, we did this study with
- 38:29Ambio for that reason. You know, our plan is to, you know, to
- 38:35look into trying to do a US based trial or trial in, you
- 38:38know, a country that is accepting to do a trial, you
- 38:43know, normal healthy control trial in this, but it's now
- 38:48going to be under a regulatory auspice, you know, under, you
- 38:50know, kind of the monitored settings that regulatory bodies
- 38:54would want. And that's not straightforward, it's going to
- 38:57take some time, it's going to take some work to get that done.
- 39:00But it's worthwhile to do.
- 39:03Yeah, I appreciate that clarification. And also it
- 39:07speaks to another aspect of Ibogaine that is unique under the
- 39:11the Lumber's categorization of psychedelics, which is that, you
- 39:16know, you could, you could effectively die as a direct
- 39:21result of what Ibogaine does when you put it in the body,
- 39:24like, you could theoretically die under LSD or psilocybin, but
- 39:28this is usually as a consequence of, you know, with the dose that
- 39:32you would have to take to directly kill you, the LD50 of
- 39:35psilocybin is massive. But you could theoretically die as a
- 39:41consequence of choices that you make when under the influence,
- 39:44but with Ibogaine, you could directly die as a consequence of
- 39:47its effect on the heart. And I understand that and I'm going to
- 39:51ask you about the study, just this next questions about the
- 39:54study, so don't go too much into it yet. But I understand you
- 39:56attempted to compensate for this potential risk with an aspect of
- 39:59variable that you put into your study design. But can you tell us
- 40:04what that risk is? Like, from what I understand, it's, it has
- 40:07something to do with the interval between heartbeats,
- 40:10that in some people, the interval can get so wide that
- 40:14the heart just stops beating completely.
- 40:16Yeah, yeah, you're very close. Yeah, that's a great, great
- 40:21understanding. So essentially, there's a there's a receptor, a
- 40:24potassium channel receptor in the heart called the HERG Herg
- 40:28potassium channel. It's very well characterized. There are
- 40:32drugs that are FDA approved that have an impact on her and so
- 40:36chemo drugs, actually some anti rhythmics can be anti rhythmic
- 40:40and pro rhythmic rarely. So they're anti rhythmic, almost
- 40:43everybody and then pro rhythmic and a small group of people. And
- 40:47in that group of people where they're pro rhythmic, I mean,
- 40:50you know, the in this case, tikka send is the drug where it's
- 40:54pro rhythmic, it can cause a widening of the q t interval,
- 40:59the interval you're talking about and the q t interval
- 41:02widening past a certain number of milliseconds increases your
- 41:08risk of going into another rhythm called torsades de pointe,
- 41:12which is a an arrhythmia that is not I became specific, again,
- 41:16it can be induced by a whole host of things. And it's a fatal
- 41:20arrhythmia, meaning that if you don't get somebody out of that
- 41:23rhythm, they're going to die. Right. And so, so, you know,
- 41:27torsades is a is a risk that that, you know, you don't want
- 41:36to have with any drug, I being has that risk. It's somewhere in
- 41:40the one in 300 range, the risk with tikka send is closer to one
- 41:44in 100 range. You know, there are other chemo drugs that have
- 41:48a risk there too. The way to deal with it is a combination of,
- 41:54as we see it prophylaxis plus monitoring, right. And the
- 42:00prophylaxis piece is utilizing a range of compounds that have
- 42:06been shown to shorten q t interval and reduce, reduce
- 42:14risk of, of torsades and other arrhythmias and q t
- 42:17prolongation. And so, you know, like, you know, IV magnesium is
- 42:21one of those potassium is another calcium is another. So
- 42:25we know those three, you know, elements can do it. oral
- 42:29lidocaine can actually do this. So there's a host of cardiac
- 42:34agents that have been shown in various experimental
- 42:37manipulations to do this. And so what's novel about this kind of
- 42:43vantage point is this idea that that essentially we can modulate
- 42:52this, this risk by, you know, by pre administering it in
- 42:59everyone. So
- 43:01the next question I had for you is now that we've talked about
- 43:06TBI generally and Ibogaine generally, specifically, I want
- 43:10to go into the study that you ran with Ibogaine. Tell me, tell
- 43:15us about your study, the design, and I guess, in some sense, what
- 43:19drew you to investigate the potential of Ibogaine for this
- 43:22purpose?
- 43:23Yeah, you know, I guess your last question first, I've, I've
- 43:27always been very interested in Ibogaine since I came across it,
- 43:30you know, more than a decade ago. You know, I was in a in the
- 43:36airport in a pretty much Central American country and, and was in
- 43:42a books, like a bookstore in that airport. And there was not
- 43:46a whole lot of English books, but for whatever reason, Breaking
- 43:51Open the Head was one of the classic Daniel, like, yeah, so I
- 43:58read that, that book, got it really interesting. And
- 44:03obviously, he has a part in there where he went and had an
- 44:05Iboga ceremony and then read a lot about it, you know, from the
- 44:11experiences that folks had written up around opiate use
- 44:15disorder. Got pretty convinced that it was a useful compound
- 44:19for that, but then thought it was reasonably unstudiable,
- 44:24right, because of the regulatory hurdles, one would have to get
- 44:28over to do something in the US, given that it's a psychedelic,
- 44:32which is kind of problem for FDA number one, especially back in
- 44:362010 or 2012, or whenever that was. And then on top of that, the
- 44:42issue of the cardiac risk, right, and the fact that, you
- 44:49know, folks had a cardiac, there's, you know, one in 300
- 44:54roughly risk of torsades and death in the opiate use disorder
- 45:01population, which I think is in part more specific to that opiate
- 45:06use disorder population, but this is a generality. And so,
- 45:11you know, you're kind of thinking in those those terms
- 45:16kept it on the radar, you know, but didn't think it was kind of
- 45:20immediately actionable, got out to Stanford working on other
- 45:23things, and then had heard about some early veterans that had
- 45:28been, you know, treated with with IBM for for PTSD, TBI
- 45:35related symptomatology depression, and kind of
- 45:41reengaged into the idea, connected with a number of folks
- 45:46that you probably aware of, you know, the vets, co founders,
- 45:53Martin Polanco, others, and talked to everybody and kind of
- 45:58came out of that conversation with a, you know, conviction
- 46:02that this was something that would, you know, would be
- 46:05helpful, you know, to folks and one needed to construct a study
- 46:10around that. So we went to the Stanford IRB and developed a
- 46:16trial that would let us, you know, evaluate veterans before
- 46:19they went to went down to Mexico to participate in this sort of
- 46:23in this sort of a study where essentially they would be
- 46:29evaluated by us, they'd go down there, receive treatment and
- 46:32then come back and be reevaluated at multiple time
- 46:34points. So
- 46:35and
- 46:37the retreats that they were going on, like your study team
- 46:43wasn't adding anything in particular, or was there
- 46:47anything specific that your study team was adding to what
- 46:50otherwise would have been or subtracting, perhaps of what
- 46:53otherwise would have been the standard sort of retreat
- 46:56experience for people before and after your testing?
- 47:00That's a great question. Yeah, you know, I mean, one of the
- 47:03things that normally happens is there's normally a five m e o
- 47:07DMT administration that that happens right after the Ibogaine
- 47:12and we delayed that past our one month follow up very
- 47:18intentionally to see an Ibogaine only effect, you know, and so in
- 47:23some ways that was specific to the study, in the sense that
- 47:28these individuals signed up to know that they weren't going to
- 47:32get the five m e o. You know, in addition to the Ibogaine, it
- 47:38really made it for a much more pure Ibogaine question. But you
- 47:44know, but we didn't, we didn't have an effect on the, you know,
- 47:48some of the other kind of sweat lodge stuff and that sort of
- 47:51stuff still happened, but was, you know, limitation in the
- 47:55right up of the trial.
- 47:56And what kind of things were you testing? Like what what measures
- 48:03were you getting before and afterwards that we're allowing
- 48:05you to track changes?
- 48:08Yeah, and so, you know, there's multiple layers and levels of,
- 48:13of kind of assessments, right? But there's like gold standard
- 48:16FDA level assessments that that, that folks use to get drugs
- 48:24approved by the FDA, right. And so, you know, there'd been a
- 48:28couple of studies out there, where folks had used kind of
- 48:32not FDA compliant sort of measures, and they saw some
- 48:36effects, and that's great. Mostly patient subjective scales,
- 48:41which have a lot of, you know, confounds because it's not, it's
- 48:47not as objective as, as a clinician rated scale, clinician
- 48:51rated scales aren't completely objective, but they're better
- 48:53than the self report scales. And so we put together like, like
- 48:59an FDA, you know, gold standard kind of level of clinician rated
- 49:04scales that we did with with everybody before after one
- 49:08month, and then we have followed it out to a year, as well as
- 49:13neurocognitive evaluations, right. And so the idea of being
- 49:18able to get a neuro behavioral readout of what various
- 49:23executive functioning scales read out to look like, as well as
- 49:30biological measures. So EEG MRI, both functional MRI, structural
- 49:36MRI. And the goal there was to get, you know, a really, really
- 49:43complete data set that captured, you know, what is the kind of
- 49:51the most comprehensive, I began related neurobiology study that's
- 49:57been conducted, right, nobody's really looked at the effects of
- 50:00Ibogaine on on the brain, and as well as kind of the most
- 50:04comprehensive clinical evaluation of what Ibogaine is
- 50:06doing, from a cognitive psychiatric neurological
- 50:10standpoint. So pretty exciting to be able to do that.
- 50:14And you measured things that had to do with their sort of the,
- 50:21like you said, so objective pictures, MRI, fMRI, EEG, this
- 50:26kind of thing. But then also, you were measuring their level of
- 50:31like how they qualify for degree of post traumatic stress
- 50:34disorder, depression, I'm not sure what else. And then the
- 50:38neurocognitive testing was because TBI, one of one of its
- 50:42primary consequences is, you know, compromised, cognitive
- 50:47function, working memory function, executive function.
- 50:50And so that's why you included those tests as well.
- 50:53Yeah, that's right. Yep. And now I understand that you there was
- 50:59something and I'm not sure if this is normally a part of the
- 51:03program, that's at Ambio, the center that you that you were
- 51:07doing this research with. But you added something else, you
- 51:12added magnesium to the treatment protocol. Can you explain what
- 51:16that was all about? And why you chose to include that?
- 51:19Yeah, so magnesium is a is the treatment for torsades to point
- 51:28the arrhythmia that that can happen with Ibogaine, it can
- 51:35happen with other drugs, actually. So anything that's a
- 51:37QT prolonging agent. And we've known for some time, and it's
- 51:42actually part of the American Heart Association guidelines to
- 51:46provide Ibogaine, I'm sorry, to provide magnesium in the setting
- 51:53of torsades. And, and so that's kind of the known treatment for
- 52:00for torsades. But there hasn't really ever been any
- 52:05descriptions of using magnesium or any other any other element,
- 52:13you know, for prevention of a drug induced torsades or QT
- 52:19prolongation. There's some studies around cardiac surgery
- 52:23related QT prolongation. And some studies around using
- 52:27oral lidocaine for for drug induced QT prolongation. But
- 52:32that's the general idea is that, you know, this, this is one of a
- 52:37host of potential cardiac protectant sort of drugs that
- 52:42could could have an effect. And so, so that's, that's the general
- 52:48idea of why that combination makes sense for that purpose.
- 52:54And was there a particular particular reason why you
- 52:59focused on a veteran population for this initial trial, or this
- 53:06particular trial, rather than sort of larger subset of TBI
- 53:12people, like why you went specifically to veterans?
- 53:14That's, you know, that's who's at this stage of the game, who's
- 53:19going down there, who's willing to go down there, you know, and
- 53:22so there've been a couple of NFL players. And, you know, there's
- 53:26some interest, you know, with with professional sports, but
- 53:29not at the level of the of the military, it makes some level of
- 53:35sense, like in retrospect, why, why that group would be willing
- 53:42to do it, right? If you think about it, they're the ones that
- 53:44are tolerant of one in 300 death risks all the time, right? I
- 53:49mean, I don't think that's what the risk is here. But that's,
- 53:52that's the kind of reported risk in the literature with an opiate
- 53:55used to sort of population. And so, you know, they before the,
- 54:00you know, before this is at scale, well, there's still, you
- 54:06know, a handful of folks, every single one of those veterans was
- 54:09pretty much accepting the assumption that they were
- 54:14accepting a one in 300 death risk. And it inherent in that,
- 54:19which is, which is pretty interesting is, you know, the
- 54:22calculation that maybe their death risk is higher with not
- 54:26doing it. Because of the suicide risks that these guys encounter
- 54:31and to my knowledge, there hasn't been a single fatality
- 54:35from Ibogaine, you know, in these individuals, but there's
- 54:40plenty of fatalities from suicide of folks that didn't get
- 54:45it. So I think, on balance, you know, we're gonna have to see how
- 54:51the data plays out. But, you know, it's, it's probably true
- 54:57that the risk is higher in the untreated groups than in the
- 54:59treated groups. But, but that's the thing that's kind of a
- 55:04speculation at this point, not something that we have any real
- 55:08super hard data on, we have like 1000, 1000 veterans that have
- 55:12gone down there, but we need to be able to do this at scale to
- 55:15really know that but it's an interesting problem, right? That
- 55:20that's hard to kind of deal with from a regulatory standpoint,
- 55:24point and like a societal standpoint, when the risk of not
- 55:29taking a drug is higher than the risk of the drug itself, or an
- 55:33intervention, it's higher than not having the intervention
- 55:36itself. And that's certainly where the state of everything is,
- 55:40right? The oral antidepressants that are out there don't have a
- 55:46particularly good anti suicide effect, you know, they don't
- 55:50really seem to have one much at all from from the, you know, the
- 55:55studies have been done. There are a handful of drugs that do,
- 55:58you know, it, you know, at scale societal levels, but in
- 56:01individual studies, don't, it doesn't play out like lithium,
- 56:05you know, and so it's one of these things where, you know,
- 56:08it'll be interesting to see is there's more work done in this
- 56:12space, if we can, you know, have a really substantial reduction
- 56:17in suicide risk. And if we do, then that's a that's kind of a
- 56:21big deal for for this group in particular, and then for society
- 56:26more generally.
- 56:27So with the group of veterans that you had going down there,
- 56:33did every one of them qualify as having, like evidence of a TBI
- 56:42either sort of report it reported evidence or something
- 56:45visible on a scan somewhere? Or were there was there possibly a
- 56:50mix? Yeah.
- 56:51Yeah, mild TBI. So mild TBI and concussion are reasonably
- 56:58interchangeable terms, you know, in the sense that they both
- 57:03refer to a traumatic brain injury that does not yield a
- 57:08structural abnormality on a standard MRI or CT scan. Right.
- 57:14So when you go and look at their brain, in the kind of normal
- 57:19scans, you don't see anything. If you look at their brain, you
- 57:23know, there's this kind of DTI diffusion tensor imaging work
- 57:28that people have done in various ways of analyzing that, where
- 57:32you can see that they're what they call pot holing and various
- 57:35things where there's small tears in the white matter tracts from
- 57:41the sharing effects of the, you know, this acceleration
- 57:45deceleration, which is effectively what you're dealing
- 57:48with, right? You know, with a TBI, I think I said this last
- 57:51time, too, that your brain is just decelerating at different
- 57:55rates, so that the, you know, essentially the brain itself is
- 58:01accelerating and stopping at a different time than the skull.
- 58:07So if you hit your, if you're, you know, if you're riding your
- 58:10bike, and you slam your head into a concrete wall, the first
- 58:14thing that's going to hit is your skull, and it'll stop. But
- 58:17your brain isn't going to stop quite yet. Right? Your skull
- 58:20stops, and then, you know, almost, you know, whatever,
- 58:24milliseconds later, seconds later, whatever it is, the, the
- 58:28brain will hit the skull and then stop. And so it actually
- 58:34decelerates on a different time scale. And when that happens,
- 58:39then you can imagine there's sharing effects on the white
- 58:43matter tracts that are in the middle of the brain,
- 58:45particularly around the thalamus. And so, you know,
- 58:50there are experimental imaging modalities that can show what we
- 58:56think are abnormalities in mild TBI, but we don't see it with
- 59:00normal structural scans. There's only one or two people that
- 59:02actually had abnormalities on a structural scan. Now, the reason
- 59:07to do that is, you know, you always kind of want to start in
- 59:12these sorts of studies with a kind of milder folks and see if
- 59:15you get an effect because if you don't see an effect there, then
- 59:19it doesn't make sense to go to more severe populations. If you
- 59:22get an effect there, then you march it up to a more severe
- 59:25cohort. And that's really, that's really what we did. So
- 59:29so everyone in your study classified under like a mild TBI
- 59:35or concussion, you didn't have anyone that had any like obvious
- 59:38brain damage or or anything like that,
- 59:40we had like one or two that had had obvious structural scan kind
- 59:45of moderate TBI. But but the vast majority of people it was it
- 59:50was, it was mild. Yeah.
- 59:53Okay, so then what did you what did you observe? Like on the on
- 59:57the other side, where you've analyzed the data now you've
- 59:59put out the paper like, with respect to Ibogaine, I guess, in
- 1:00:03addition to magnesium, it seems like magnesium was less about
- 1:00:06adding to the Ibogaine effect than taking away from the from
- 1:00:10the risk.
- 1:00:11Yeah, that's right. Exactly.
- 1:00:12What did you see? Were the like, what did you observe is the
- 1:00:17effects Ibogaine had on these veterans with TBI and the
- 1:00:22variety of their symptoms?
- 1:00:24Yes, so we saw a reversal of traumatic brain injury
- 1:00:29disability. We saw a improvement across a broad range of
- 1:00:36idiopathic psychiatric illness or depression, PTSD, anxiety,
- 1:00:41and reduction in suicidal ideation, and that, you know,
- 1:00:47reversal of disability on the hudas. And so it's, you know,
- 1:00:52that was the particularly robust finding was seeing that, you
- 1:00:58know, one month, most of these folks had gone into no
- 1:01:01disability from mild to moderate disability, which is pretty
- 1:01:05striking.
- 1:01:06And what about the cognitive function? Like, was there a
- 1:01:12notable change in people's cognitive functioning as well?
- 1:01:15Yeah, the cognition improved across the board as well. Yeah,
- 1:01:19so it was pretty great.
- 1:01:21How, how significant are these results in the sort of like,
- 1:01:25larger field of TBI treatment?
- 1:01:28Well, there's no, there's no kind of biological therapeutic
- 1:01:33for TBI. And so everybody is always looking for TBI
- 1:01:39therapeutics that would be of interest, you know, and this is
- 1:01:41definitely, you know, one that that's promising, you know,
- 1:01:47there was a an editorial that accompanying editorial written by
- 1:01:53Dave Brody and Sean Siddiqui or TBI researchers, and they, you
- 1:01:57know, they felt that the study was compelling and worthwhile
- 1:02:01pursuing more, you know, data on. And that's important, you
- 1:02:05know, because they've been really the only ones, you know,
- 1:02:09that have had recent signals of effect with transcranial
- 1:02:12magnetic stimulation, you know, and so they kind of leaned in on
- 1:02:16this too. So I think the idea that, you know, more studies
- 1:02:20need to be done, we need to do a controlled trial, you know, it
- 1:02:24needs to go through the standard, you know, science
- 1:02:27process to kind of move it forward. So
- 1:02:29I guess like, I, I have the question of something like,
- 1:02:38because your response was very tempered there, and the sort of
- 1:02:43reporting around it, which I don't expect you to take the same
- 1:02:46raw raw that sort of reporting on science as a scientist, I
- 1:02:50imagine you don't want to sound like a science reporter, those
- 1:02:53are different roles. But my sense was that, that these
- 1:02:58results are, they're really substantial in the sort of in
- 1:03:05in the sort of, oh, yeah, we sent people down for this
- 1:03:07singular treatment. And it had these these seemingly massive
- 1:03:10changes in an area of medicine and therapy, that at best is
- 1:03:17incremental, and slow over time, if not a lot of the time, almost
- 1:03:22entirely ineffective to get people out of a disability
- 1:03:25state.
- 1:03:25Yeah, you know, there's levels of knowing, right. And the
- 1:03:34greatest level of knowing in this case would be a multi site
- 1:03:38trial that other people conduct that follow, you know, this
- 1:03:44protocol and find the same thing with a blind in place. And
- 1:03:48you'll see me out saying a bunch of really compelling things that
- 1:03:52are definitive. If I if I sit on the show, and I tell you, yeah,
- 1:03:56this is definitely a treatment. And this is, you know, and my
- 1:04:03colleagues that do this sort of work would, would, you know,
- 1:04:07would have me at the stake or whatever. Because we don't, we
- 1:04:13don't really know, you know, we, I mean, in theory, and that's
- 1:04:18why nature medicine, you know, had us put all this extra stuff
- 1:04:22in there, you know, we, you know, we had to list the sweat
- 1:04:28lodges and the this and the that that were going on down there.
- 1:04:30Now, we know in isolation, that none of that actually produces
- 1:04:36like robust changes in their own right. I think the reason why
- 1:04:39MBO does that is very good. I'm not trying to detract from that.
- 1:04:43But it's, it's likely, it's likely not the primary mechanism
- 1:04:47of improvement here. It's likely that the the drug itself was but
- 1:04:51without having like a really sterile, non therapeutic
- 1:04:58environment with no activities, they're therapeutic, you know,
- 1:05:02you're, you're basically pulling all that out of it and creating
- 1:05:06an environment which everything's neutral other than the
- 1:05:09treatment itself, then you, you don't, you can't make the same
- 1:05:15level of claims. But on the flip side, you know, nature medicine
- 1:05:19was willing to publish it. And so everybody believes the signal
- 1:05:24is really there. But, you know, to really know, you gotta, you
- 1:05:27gotta jump through all the hoops. And it's, you know, the funny
- 1:05:32thing about that is that it's, it's just this is a modern day
- 1:05:37convention. That's not necessarily how things got into,
- 1:05:41you know, into the pharmacist closet forever, right? It's just
- 1:05:48more of a, you know, modern thing. So, you know, I did a TEDx
- 1:05:52talk recently, I may have talked to you about this in the
- 1:05:54earlier half of the show, but looking at thinking about how to
- 1:05:58really think about these results in the context of history. And
- 1:06:01so talked a lot about scurvy and how we knew, you know, that
- 1:06:08vitamin C and, I mean, eventually vitamin C, what was
- 1:06:11vitamin C containing fruits were necessary for treating scurvy.
- 1:06:17And, yeah, there was there's levels of knowing, right? And
- 1:06:22that's, that's definitely, you know, that's definitely there
- 1:06:27embedded in history. But like needing a fully blinded study to
- 1:06:31know isn't necessarily the way we've always done it. But it's
- 1:06:36certainly modern convention. And in order to get things through
- 1:06:41and not have people point to something and say, yeah, that's
- 1:06:44you don't know, really, you have to do it that way.
- 1:06:47Now, it's interesting, like, of course, I can appreciate that. I
- 1:06:52understand that. And it's also interesting to consider that in
- 1:06:55the context of a psychedelic molecule, we'll say, you know,
- 1:07:00obviously, Ibogaine doesn't fit the classical group, but it fits
- 1:07:04at least loosely into the psychedelic category. Because so
- 1:07:08much of because psychedelics are not like an aspirin, right? I
- 1:07:12take an aspirin, it's got a pretty dedicated result, I take
- 1:07:16it, and it's gonna do what it's supposed to do, it's going to
- 1:07:19have that pharmacological effect where with psychedelics, the
- 1:07:23medicine of the psychedelics, so much of it is influenced by
- 1:07:27context, like somebody could take five grams of mushrooms in
- 1:07:31one context, and it can heal their depression, maybe they
- 1:07:35could take it in another context. And they've got depression plus
- 1:07:39post traumatic stress disorder from being an absolute terror
- 1:07:41for whatever, six hours. And so it I guess I was going to save
- 1:07:47this question a bit more for later, but I guess I'll kind of
- 1:07:50like weave it in now, which is that, you know, like, how much
- 1:07:54do you think the the the benefits that you're seeing, the
- 1:07:59changes that you're seeing are purely because of the molecule
- 1:08:03itself, physical molecule, physical brain, physical change,
- 1:08:08and how much of it might be influenced by the sort of like
- 1:08:12larger therapeutic container that allows for those changes to
- 1:08:16take place, or the larger therapeutic container that
- 1:08:19allows for these experiences not to be troubling so that they're
- 1:08:24more, you know, inclined towards like a like a positive
- 1:08:28valence.
- 1:08:28Definitely. Yeah, I mean, I think that, you know, we society
- 1:08:38and Western culture and kind of the scientific method and kind
- 1:08:43of how the medical establishment sees how to deal with things.
- 1:08:48It's all like centered around certain assumptions about
- 1:08:53reality, and about what's therapeutic. And if you're
- 1:09:00talking about a knee infection or skin infection, or, you know,
- 1:09:06osteoarthritis, or whatever it is, you know, I think you can
- 1:09:11be reasonably sure that, although some people may disagree
- 1:09:16with me on this, but reasonably sure that those assumptions are
- 1:09:19are pretty valid, you know, that, you know, you've got this
- 1:09:25infection, you take this antibiotic, the antibiotic has
- 1:09:28an effect on the bacteria that kills the bacteria that ends up
- 1:09:32you know, resolving your, your, you know, bacterial infection,
- 1:09:36your skin or whatever it is, right? You know, and that's,
- 1:09:40there's, there's good evidence that, at minimum, that
- 1:09:45particular approach is one effective way of taking care of
- 1:09:52that problem, right? With, with psychedelics, the problem is, is
- 1:09:59that it kind of gets in the way of assumptions and, and
- 1:10:05philosophical kind of framework of Western medicine, right?
- 1:10:10Because we should just be able to give the pill. And it doesn't
- 1:10:15matter what the person's thinking or doing that the pill
- 1:10:17just kind of works, right? And that's how like, you know, heart
- 1:10:21pills work, antibiotics work, and blah, blah, blah. The problem
- 1:10:30with, with the psychedelics is that this is, this is something
- 1:10:36that's a nonspecific enhancer of certain experiences,
- 1:10:41particularly MDMA, I would say that one. In particular, it's
- 1:10:47important. And I'd argue that classic psychedelics are
- 1:10:49somewhere in the middle. And I think I began to is very
- 1:10:52important that people feel safe and in a container, but it's not
- 1:10:55as much psychedelic assisted psychotherapy, and it's more its
- 1:10:59own, its own kind of framework. And so that's the, that is the,
- 1:11:08the kind of thinking behind that. And because of that, I think
- 1:11:14that, you know, we're gonna have to really grapple with this idea
- 1:11:17that even more so than the normal with a vulnerable
- 1:11:23patient, this is kind of an extreme of a vulnerable patient,
- 1:11:27and we have to really set a framework up for those extreme,
- 1:11:32you know, vulnerabilities that all patients taking these
- 1:11:35compounds are in. And, you know, people try to tackle this with a
- 1:11:40male and female therapist and in all of these kind of settings
- 1:11:44to be able to try to safeguard against it. But I think we're
- 1:11:48gonna have to really think really deeply about what
- 1:11:52interactions and what words are spoken and all of that in a
- 1:11:56highly plastic state. You know, the the area where this has been
- 1:12:02solved out at some level, which is really interesting, is in
- 1:12:06therapeutic hypnosis. Right, every word that's spoken by the
- 1:12:11hypnotherapist is intentional, the person is in an altered
- 1:12:16state, very vulnerable in that altered state. And the
- 1:12:19hypnotherapist is very clear about what they're saying and
- 1:12:23not saying to the patient, and the setting in which they're
- 1:12:26producing for the patient. And there's a long, you know, and
- 1:12:30that's the first conception of Western psychotherapy, and it's
- 1:12:35effectively inducing an altered state. And so that's why I've
- 1:12:39been pretty interested. We've done some hypnosis studies,
- 1:12:42we've actually been able through neurostimulation to change the
- 1:12:46trait, make people transiently more hypnotizable. And the goal
- 1:12:51of all that is really to understand how do you access
- 1:12:56that altered other place, and what's in there? And what are
- 1:13:03the the bounds of it? What are the contexts of it? And so in
- 1:13:06some ways, that's very similar to what you're talking about.
- 1:13:12Do you think that it's possible that if in a future study,
- 1:13:21people with similar sort of clinical diagnoses and set of
- 1:13:26symptoms, etc, are brought into a, you know, very clinical
- 1:13:31space, and are just given the Ibogaine with somebody there to
- 1:13:36just track them from like a pretty standard place, nothing
- 1:13:40special, nothing extra therapeutic, just safety
- 1:13:42protocol, trying to sort of like, eliminate the humanity as much
- 1:13:48as possible to create this kind of objective, drug only measure.
- 1:13:52If it turns out that those people aren't getting as much
- 1:13:55benefits, you know, according to your study, or in a larger
- 1:13:59therapeutic container, like was present at the at the Ambio
- 1:14:02Center, that that suggests that do you feel like that would be
- 1:14:07like a cue to reconsider Ibogaine? Or would that be a cue
- 1:14:11to sort of even further consider facilitation context to support
- 1:14:17the positive outcomes?
- 1:14:18I think the latter, I mean, I think the thing about Ibogaine
- 1:14:21is really interesting is this life review slideshow that
- 1:14:24people talk about seems to happen, irrespective of any
- 1:14:27sort of psychotherapeutic interactions, right? And so
- 1:14:31Howard Lotsoff, who was a poly substance user, who was, you
- 1:14:36know, the first person in the US that really kind of tried to
- 1:14:38champion Ibogaine, ordered online for the purposes of
- 1:14:43recreation, and found quite quickly that this is not a
- 1:14:47recreational compound and came out of that, no longer desiring
- 1:14:53to use any sort of, you know, substances and to my knowledge
- 1:14:57never really did after that point. And, and he, I think he
- 1:15:03like ordered it, man order or something and didn't have a,
- 1:15:06didn't have a container. And so I think, I'm not suggesting that
- 1:15:10people do that. But it's, it's, it's probably the case that some
- 1:15:16people need more support. It's probably the case that some
- 1:15:18people need less support. And the question is, how many people,
- 1:15:23what percentage of people need more support? What does that
- 1:15:25support look like? Or, you know, vice versa? I have, I'm a
- 1:15:31scientist, I have no opinions on this. I run a clinic and all,
- 1:15:36you know, I don't have any agenda around saying, my way is
- 1:15:40the way, you know, I don't have, I don't have any beliefs about
- 1:15:44that. I think that, you know, where I sit, there's a signal
- 1:15:48there that's really robust, that we have to figure out what's
- 1:15:52driving it could be all a host of things. I'm totally open to
- 1:15:57the idea that the therapeutic environment is mandatory for its
- 1:16:02effect. I'm open to the therapeutic environment being
- 1:16:05less mandatory for its effect. I don't, I don't have an agenda
- 1:16:10there. I, I think it's always best to have a safer
- 1:16:15environment. And then you scale down the acuity of that safe
- 1:16:19environment. And that's what we're going to have to do in
- 1:16:22order to be sure that we don't cause harm, which is one of my
- 1:16:26like, Hippocratic Oath things is to, to not cause harm, right? So
- 1:16:31I have to do that. But the idea that, you know, there's more or
- 1:16:37less necessity for this, it's just, it's very unclear, because
- 1:16:41people haven't done the work to figure that out. I think Robin
- 1:16:44Cart Harris, up at UCSF is, is looking at this question as it
- 1:16:48relates to psilocybin assisted, you know, psychotherapy, whether
- 1:16:54the, you know, the actual psychotherapy, you know, set and
- 1:16:57setting pieces, important or not, I think he's gonna, he's
- 1:17:01gonna help to try to sort that out for psilocybin. But it's one
- 1:17:05of these things where you have to almost do that trial. And the
- 1:17:08problem is these, I mean, trials gonna be really hard to do, you
- 1:17:11know, and so it's gonna be a while till we answer that. So I
- 1:17:15think whatever ultimate design comes up from just the base
- 1:17:20trial, it will be scrutinized, and then we'll have to kind of
- 1:17:24figure it out from there.
- 1:17:27So let's take a couple steps back to a to the question we were
- 1:17:30on there about, you know, how your results compare to other TBI
- 1:17:34treatments. I mean, pharmacologically, from what I
- 1:17:39understand, we don't have any drugs that that fix the damage
- 1:17:44that, you know, the symptoms of TBI come from mostly we have
- 1:17:47drugs that mask symptoms or support people through their
- 1:17:51symptoms long enough that the brain can hopefully heal itself,
- 1:17:54various non pharmacological treatments that could support
- 1:17:57things.
- 1:17:58You have drugs that like treat like, say, you know, spasticity
- 1:18:03and things like that from traumatic brain injuries. So
- 1:18:05there's not nothing but but it's, you know, they're daily
- 1:18:09drugs, it's Botox or something. But there's nothing that
- 1:18:12certainly is helped with reversing any of the major
- 1:18:15cognitive deficits in any robust way, people use stimulants and
- 1:18:19stuff like that. But it's not, you know, not at the level that
- 1:18:22it's certainly not a single administration that lasts for a
- 1:18:25long time. That's what's really striking about this. So I think,
- 1:18:30you know, it's very compelling, because it looks like it's a
- 1:18:34neurotrophic, you know, factor up regulator, it's, it's, it's not
- 1:18:40like you have to keep taking this every day, it's like you do
- 1:18:42it, and then it persists for, you know, we have day, you know,
- 1:18:46your one year data, it's persist forever.
- 1:18:49Really, one year, it's still persisting the benefits people
- 1:18:52had in your wow. Yeah, that's very promising. Or like, I feel
- 1:18:57it feels very promising, because I myself am living with post
- 1:19:00concussion syndrome. And I felt the sort of yo yo of trying to
- 1:19:04find the right treatments and so on and so forth. So yeah.
- 1:19:07Yeah, it's, it's, it is, it is very compelling. And you know,
- 1:19:11placebo degrades quite quickly, right? And so you can have a in
- 1:19:17treatment naive people, you can have a pretty robust placebo
- 1:19:20effect, but the placebo effect generally degrades quickly over
- 1:19:26time. And so the idea that this didn't degrade over time makes
- 1:19:31it more probable that there's something real about it. While
- 1:19:35it's not a controlled trial, at least, you know, that's, that's
- 1:19:39a compelling feature. So that's, yeah, we're trying to, we're
- 1:19:43trying to, you know, sort a lot of that stuff out and kind of
- 1:19:46move forward on some of that. So yeah.
- 1:19:48Now, how do you think I began? Okay, so there was a, a paper
- 1:19:57that came out, I think within the last two or three years,
- 1:20:01specifically looking at psychedelics, you know, writ
- 1:20:04large as possible agents for treating brain injury, because
- 1:20:11of their sort of neuroplastic effects, neutrophic effects,
- 1:20:16etc, ranging everything from including MDMA and the classical
- 1:20:20psychedelics, as well as ketamine, I myself have received
- 1:20:24ketamine as a as a TBI treatment. Do you think that the
- 1:20:29same principles? Maybe that's not the question. It's more
- 1:20:33like, how do you think or what's your thoughts on how your
- 1:20:40observations with Ibogaine, do you think that they're also
- 1:20:43going to apply to other psychedelics as well? Or is there
- 1:20:48something special about Ibogaine you think that's having such a
- 1:20:51seemingly robust effect?
- 1:20:53I mean, it seems to be a longer acting drug, it seems to have a
- 1:21:01broader pharmacology. I mean, it doesn't seem it does have a
- 1:21:05broader pharmacology that affects more neurotransmitter
- 1:21:08systems. And so we, you know, we think that's probably a big
- 1:21:12piece of what's playing into what's driving that, you know,
- 1:21:17that range of effects. So yeah, it's, it's, but it's early days,
- 1:21:21you know, the basic science hasn't even been really well
- 1:21:26worked out on this yet. So
- 1:21:28so I think you've maybe alluded to it generally. But is there
- 1:21:37like, do you have any sense of or theories as to why the Ibogaine
- 1:21:42itself has this effect on participants, sort of like
- 1:21:46underlying TBI issues and their symptoms? Like you did mention,
- 1:21:51it has this neutrophic effect, you mentioned this life review
- 1:21:53effect, based on the pharmacology of Ibogaine, do you
- 1:21:58have a sense or a theory as to like why it is that it seems to
- 1:22:01be having these robust, these robust effects on the brain
- 1:22:06specifically?
- 1:22:07Yeah, I mean, there's, you know, like one way of dealing with
- 1:22:13that question, which is to say, Oh, it's just this broad acting
- 1:22:15kind of dirty drug. And that's way like most people would, what
- 1:22:19most people would say to you. And they say the same thing
- 1:22:21about ketamine. Oh, it's just this dirty drug that has these
- 1:22:24broad effects or whatever.
- 1:22:26And to be clear, dirty just means that it's sort of like,
- 1:22:29it's it's promiscuous with how much effect it has. Yeah.
- 1:22:33Promiscuous. Yeah, it dances with everyone or whatever.
- 1:22:37Right. You know, the reality is, is that dirty also implies
- 1:22:43random. Random effects, and it just kind of randomly does x, y
- 1:22:52and z that it does. You know, things in nature aren't that
- 1:22:57random. They may seem random. But, you know, evolutionary
- 1:23:04pressures create solutions for problems, you know, based off of
- 1:23:11the pressure that's exerted being exerted on that plant or
- 1:23:15animal or whatever it is, right. And in that way, in kind of in
- 1:23:19the microwave, that is random, too, in the sense that like, you
- 1:23:24know, bird number one is got a yellow or beak because that
- 1:23:31helps them, you know, ward off this that or the other. And so
- 1:23:35on this island, that's the case, you know, that's kind of random
- 1:23:37in some sense. But, you know, but in some ways, it's not
- 1:23:42random, right? Like, you know, force one exerted pressure on on
- 1:23:47on animal or plant to and something happened. So the
- 1:23:53question is, how random is these very specific, very interesting,
- 1:24:00seemingly quite therapeutic, sort of psychological effects of
- 1:24:05Ibogaine, you know, is it really, like, just completely random,
- 1:24:09that all just played out, you know, or not. And most people
- 1:24:16would say yes, I'm just not sure. I think saying yes, and, you
- 1:24:21know, assumes a level of understanding that we don't
- 1:24:24actually have, you know, about what, why that really remarkable
- 1:24:32compound sitting in a rainforest shrub in the middle of Central
- 1:24:37West Africa and, and why we were drawn to use it and continue to
- 1:24:43use it, right. I think I think that it's probably not as random
- 1:24:48as people would assume.
- 1:24:50What about pharmacologically? Like, what do you think there
- 1:24:56might? Do you have a sense of what it might be about Ibogaine
- 1:25:02as a compound and its effects on the brain that allow it to, like,
- 1:25:07my assumption is that, is that and maybe this was supported in
- 1:25:12your in your fMRI or your your, you know, the scans and
- 1:25:17something that you took. But my assumption is that the
- 1:25:20resolution of these TBI symptoms after the Ibogaine is likely
- 1:25:25correlated with some sort of physical change to the structure
- 1:25:29of the brain, some repair of the sheared, I can't remember, he's
- 1:25:33a dendrites or something, but basically, like repairing some
- 1:25:36damage. And that it's not just like, oh, it's not just up in my
- 1:25:41mind, I'm thinking differently now, but there was some sort of
- 1:25:44structural change to the brain that would allow for the
- 1:25:46resolution of these symptoms. Is that correct? And if so, or if
- 1:25:51not, why do you think that might be the case?
- 1:25:54Well, I think that Ibogaine certainly has this neurotrophic
- 1:26:00effect that's probably driving some of the biology just
- 1:26:03described if that's in fact, we need to do a lot more work to
- 1:26:06prove that out. But but, you know, like I said, I mean, I
- 1:26:11think the way that I think about Ibogaine, which is really
- 1:26:14interesting, almost counterintuitive is, you know, we
- 1:26:18have this psychopharmacology, psychopharmacological kind of
- 1:26:26way of thinking about drugs right now, that's like a 15th
- 1:26:31century key, you know, talking about like the single tooth on
- 1:26:34the metal rod, right? That's right. The modern day key is much
- 1:26:39more complicated than that it interdigitates with, you know, a
- 1:26:42whole host of pins that ultimately causes for the door to
- 1:26:45be unlocked. Right. And, you know, I think the human brain is
- 1:26:51a lot more like the modern day key, and a lot less like the
- 1:26:5615th century key. So we've been trying to jam a 15th century key
- 1:27:01into a modern day keyhole. And I think Ibogaine is a lot more
- 1:27:05like a modern day key. It it it interdigitates with a whole host
- 1:27:12neurotransmitter systems. And it does so in a very sophisticated
- 1:27:16way. And because we don't have tools to understand the concert
- 1:27:25level effects, and we're still stuck on trying to understand
- 1:27:29what the violin is doing, we don't really have a way of
- 1:27:32answering your question. Right. I hope that's helpful
- 1:27:36metaphorically.
- 1:27:37No, it is very helpful metaphorically. So I appreciate
- 1:27:41that. I got two final sort of larger questions and then one
- 1:27:46sort of closing question. Now, I've heard some reports. This,
- 1:27:51you know, I don't know where it came from. I can't remember if I
- 1:27:55read it in your study. I don't think I did. But I've heard
- 1:27:57other people report on this idea that Ibogaine can de age the
- 1:28:00brain. What do you have any knowledge of that of that
- 1:28:06proposition and what your thoughts are on it?
- 1:28:10Yeah, so Ibogaine can can reverse brain age estimations by AI
- 1:28:21algorithms per our data. It's unpublished, but everybody and
- 1:28:26their brothers talking about this. My talk in Denver, I it
- 1:28:33makes me a little bit nervous, because I think we need to do a
- 1:28:36lot more before we actually really know that, you know, but
- 1:28:41but you know, that's a signal that that's there that may be
- 1:28:44true. And, and why it does that again is, is kind of unknown to
- 1:28:50me. But I think it's important if that's true, because, you
- 1:28:54know, people probably would want that to be something that that
- 1:29:01we know. So that's that one. And then, yeah, what was your second
- 1:29:05question? I mean, I think that that was the question around,
- 1:29:08oh, like, essentially, like, is, is that the case? And if so,
- 1:29:14what your thoughts were around why or how, but I imagine that
- 1:29:18the the wire how is goes back to that, that metaphor about the
- 1:29:22modern key versus the 15th century key.
- 1:29:24Yeah, I mean, if you think about it, like, if we are 15th
- 1:29:29century key makers, and you give, if you go back to the 15th
- 1:29:32century, and you give a key maker, a modern day lock, and
- 1:29:35they look at that, their mind's gonna blow up, right? And so
- 1:29:39you're asking a 15th century key maker to understand your modern
- 1:29:43lock, or your modern key or whatever. And the idea, now, if
- 1:29:51you gave that to them, and had them take it all apart and take
- 1:29:55a look at it, and then go and try to build a new one, would we
- 1:29:58have had modern day keys earlier in time? Absolutely. Right? It
- 1:30:03would have sped up the key and lock technology, maybe by 100
- 1:30:08years or whatever, because they'd have been able to inspect
- 1:30:11and look at this. And that's the value of psychedelic research,
- 1:30:14right? Is this ability to, you know, we've been muddling around
- 1:30:18with 15th century keys, we've been trying to optimize a
- 1:30:2515th and a half century key or something. And now all of a
- 1:30:28sudden, we've got this modern day key and lock in front of us,
- 1:30:32we're able to use it again. And we're looking at it and going,
- 1:30:35well, gosh, you know, that 15th century keys, not very good. And
- 1:30:39this one's really good. But God, I don't even know how to begin
- 1:30:43to understand how this works. Because it's so many pins, it's
- 1:30:48so many interactions of the key with the thing. And we're just
- 1:30:51so used to this one tooth with variable heights. And that's it,
- 1:30:55right? Like, that's really like the simplistic way we've been
- 1:30:58dealing with pharmacology. And so to, you know, to, to kind of
- 1:31:04go, go into that and try to have any explanation, real
- 1:31:09explanation, I mean, give you hand waving, but any real
- 1:31:12explanation about what is going on there would be me making up a
- 1:31:16story for you. And people like to make up these stories and say
- 1:31:20things. But I don't, you know, I just acknowledge the fact that
- 1:31:23we don't have the tools.
- 1:31:24One thing that was interesting when you when you use this, oh,
- 1:31:29now we have this new modern day key as 15th century key makers,
- 1:31:34I, you know, I couldn't help but think about sort of, well, I'll
- 1:31:40just leave this as just like a throwaway reference or whatever,
- 1:31:44but just kind of like in our modern kind of so much research
- 1:31:48is being led by profit agenda, especially in pharmacology, from
- 1:31:52what I understand is like, can we make a marketable drug? If not,
- 1:31:55like, let's not fund this research, or so on and so forth.
- 1:31:59But when I think about it, this very reductionist, like bringing
- 1:32:03it down to the basic single thing, you know, single pin,
- 1:32:07single key, so on and so forth, and when you're talking about
- 1:32:10bringing in this advanced modern day key, it's also interesting
- 1:32:15because it's you're also saying, well, well, actually, we're
- 1:32:18bringing back this other thing that existed for 1000s of years,
- 1:32:22in other cultures before we developed the single key and
- 1:32:25now wondering how to sort of like, up level our whole key
- 1:32:28process now that we're sort of analyzing based on the reference
- 1:32:32of these like ancient tools. I've again, obviously being used
- 1:32:36for a very long time, from what I understand, or the plant
- 1:32:39Ebola likely longer than, you know, we're making keys.
- 1:32:44Yeah, you have to separate high technology from time. That that
- 1:32:49TED talk that I just gave the whole like, essentially set of
- 1:32:56assumptions that was in there was that it's about separating
- 1:33:01time from technology and that we have linked the future with high
- 1:33:10technology. And in the pharmacological space is not true,
- 1:33:14in my view, right? And some I mean, some drugs that we made
- 1:33:17that are outside of the CNS, that's, it's probably true, some
- 1:33:20new chemo drugs or whatever. But, but as far as like, what do
- 1:33:25you do with somebody with depression? You know, I think
- 1:33:28the SSR eyes that humans have made are very impressive, right?
- 1:33:33They're kind of like old tech in many ways. And psychedelics are
- 1:33:39more high tech, you know, and so this idea that you can separate
- 1:33:45time, linear time from technological sophistication.
- 1:33:51Right. And I think that that's where people get really stuck.
- 1:33:56The idea of getting drug companies to get, you know,
- 1:34:02psychedelics through and having a profitable drug to me is
- 1:34:06unrelated, relate, right? Like, you know, let them do that.
- 1:34:13Because that's the only way you're going to get this out to
- 1:34:15people, you know, people have this, especially the
- 1:34:17psychedelics, basically, well, that shouldn't happen. And all
- 1:34:19this reality is those people live in Northern California,
- 1:34:24have the financial means to go buy their psychedelics from
- 1:34:29wherever and get to go on an ayahuasca retreat, because they
- 1:34:33have the money to go down to Peru. The, you know, what these
- 1:34:37companies are doing is they're really getting access for people
- 1:34:41to get this through Medicare that are on disability that
- 1:34:44don't have access. Right? Like, in some ways, I find it'd be
- 1:34:50kind of counterproductive to think about things like that.
- 1:34:53So I think that's that, which I think is really just about
- 1:34:57getting psychedelics to the masses when you threw a vehicle
- 1:35:00of capitalism, right? You can have a view of that or not have
- 1:35:04a view of that. And then there's a separate agenda around using
- 1:35:08and understanding these drugs to either make new drugs, or to
- 1:35:13refine how the drug is administered, or what it's doing,
- 1:35:18or to understand something about the brain. And I think they're,
- 1:35:22they touch each other. But they're, they're, they're
- 1:35:26really separate issues, you know, and they're probably gonna
- 1:35:31be companies that do the second thing too, which is going to be
- 1:35:34ultimately more important, but to get this thing done to
- 1:35:37normalize this whole space, and to be able to say this is
- 1:35:41actually a treatment, you know, that's actually a policy
- 1:35:44importance.
- 1:35:45Yeah, and the policy follows. Well, hopefully it follows
- 1:35:50research, usually, a decade behind from what I understand.
- 1:35:54But yeah, this is good. I'd like to I'd like your comments there.
- 1:35:57I, I've heard Dennis McKenna talk often around like trying to
- 1:36:04nudge big pharma companies and big otherwise, like massive
- 1:36:10thing, massive corporations, or just basically like economic
- 1:36:15super forces to be like, hey, you should save the rainforest
- 1:36:18because your next billion dollar drug might be in there. And if
- 1:36:21you plow it down, you're never going to find it.
- 1:36:23And I think he's spot on with that. Right? I think he's 100%
- 1:36:29that is 100% true. And that's absolutely what they should be
- 1:36:32doing. You know, and I think that's 100% right. And I think
- 1:36:36that's the value of those entities, right? It's, you know,
- 1:36:41if Pfizer could go in and buy, you know, 5000 acres of the
- 1:36:47rainforest and preserve, you know, all that vegetation and
- 1:36:51study it, it would it would behoove them to do that. That's
- 1:36:551000% true. And it's the right thing to do for the world, you
- 1:37:00know, and I think I think he's he's spot on about that. So yeah,
- 1:37:05it's, if there was some big, you know, some big pharma company
- 1:37:12that grew out of doing psychedelic, you know, approvals
- 1:37:16and that one went in and was able to, you know, preserve,
- 1:37:20preserve the rainforest or preserve Gabon's, you know, I
- 1:37:25boga tree supply and give back to the people or something like
- 1:37:28that. I think that's a huge win. You know, I think that you know
- 1:37:31what I mean? I think, but it's got to be that right. It's, it's
- 1:37:35got to be this kind of hand in hand dance between how do you
- 1:37:38give? How do you get everybody access? How do you give back?
- 1:37:44And I think if we can figure out a good way of doing that, then
- 1:37:47you can use capitalism as a vehicle for good.
- 1:37:49Giving back and hopefully over time taking less, but that taps
- 1:37:56into the larger sort of force of the consumption machine that
- 1:38:01capitalism is presently sort of, you know, banking on. But that
- 1:38:06was kind of intended as a throwaway reference. I really
- 1:38:09appreciate that you brought your mind to it. I want to ask you
- 1:38:11this, this sort of final larger question before I kind of ask
- 1:38:17you what's next and yada, yada. So based on what you so I'm going
- 1:38:26to ask you to speculate something based on what you know
- 1:38:29now about Ibogaine, what you know and don't know about Ibogaine,
- 1:38:32Ibogaine treatment, TBI, etc. Could you speculate on what the
- 1:38:37potential efficacy might be for smaller long duration
- 1:38:42administration of Ibogaine for TBI? Of course, I'm talking about
- 1:38:46micro dosing here. But I do understand that there's a, there's
- 1:38:49some relationship to the neurotrophic effects between the
- 1:38:53immediate action of Ibogaine and the longer, you know, impact of
- 1:38:58nor Ibogaine is one of its metabolites and so on and so
- 1:39:00forth. Maybe that's a part of it, maybe not. But yeah, anything
- 1:39:03that you'd be able to offer on that.
- 1:39:05Yeah, but we just don't I mean, the big thing is we just don't
- 1:39:08know, because we know even less about that. But I would say that
- 1:39:11you know, the French were using low doses of Ibogaine from 1930
- 1:39:18to 1966. And while there's not really the, you know, the data
- 1:39:23back then is, you know, very scant is like a, is like a, you
- 1:39:29know, a positive spin on, you know, maybe non existent on
- 1:39:33what, you know, what that was. I think it's important to kind of
- 1:39:37understand that, you know, that that that drug was was around at
- 1:39:43micro dose levels for a time. And the reality is, is that if
- 1:39:47people didn't didn't have benefit for doing that, then it
- 1:39:53wouldn't have been a product, right? And so, you know, there
- 1:39:58are plenty of things that that were offered up as potential
- 1:40:02cures for various things, and probably had a similar sort of
- 1:40:05placebo effect possibility and didn't stick around for 36
- 1:40:10years. You know, but low doses of Ibogaine did. And so as a base
- 1:40:14case, I'd argue that just the sheer fact that it was around
- 1:40:18for multiple decades and utilized, you know, suggest
- 1:40:23there was something there. Now what, beyond that, I can't
- 1:40:28really talk much about the data. But I but my, my suspicion is
- 1:40:32that that's going to be an area that's going to be really
- 1:40:35studied over the course of the next couple of years, the decade
- 1:40:38to really sort that out.
- 1:40:41Yeah, it is it is very, it's very interesting to me, I think
- 1:40:45explicitly because, you know, if I consume psilocybin, it
- 1:40:49metabolizes and is like out of my system in a very short amount
- 1:40:53of time, the metabolize from what I understand have little to
- 1:40:56no sort of ongoing effect. But with Ibogaine, nor Ibogaine has
- 1:41:02several other like clinically relevant effects, and it will
- 1:41:06build over time because it's fast soluble, it can build up in
- 1:41:09your neural tissue over time where you take small amounts
- 1:41:12every day, eventually you get to the place that you've built up
- 1:41:15enough nor Ibogaine in your system that might mimic what
- 1:41:19would have been there after a single flood dose. Now, that's
- 1:41:23based on what I understand, which is, excuse me, you know,
- 1:41:27clearly, clearly less than the data set that you're working
- 1:41:30with. But I do find it something as something uniquely
- 1:41:37something unique in the micro dosing space that it might have
- 1:41:40to offer. Mind you, and maybe you could answer this is, you
- 1:41:45know, Ibogaine still has this cardiac risk. And my assumption
- 1:41:49is that perhaps, you know, micro dosing it over a month long
- 1:41:54might introduce that risk, it might not. I don't know. Again,
- 1:41:56I assume we don't have this data.
- 1:41:57Yeah, I mean, we, we don't have a sense that I mean, it's scant.
- 1:42:04So you don't know, we don't really know this. But I didn't
- 1:42:08get the sense that the really low dose Ibogaine in the French
- 1:42:10population, you know, had any, there's, there's nothing in the
- 1:42:15literature to suggest that that had, you know, a cardiac risk
- 1:42:19that was, that was written down, you know, and so, you know,
- 1:42:24whether it did or not, I bet, I bet you couldn't really know
- 1:42:27that. But it, I would think that you'd have some sense that that
- 1:42:33could have been present, really, a lot of this stuff ends up
- 1:42:36being, you know, dose related anyways, that was several
- 1:42:39orders of magnitude less than a flood dose. And so, so my
- 1:42:43suspicion is, is that I'm not gonna sit here and tell you
- 1:42:45there's no risk. But my suspicion is that there's less
- 1:42:48risk, if you look at the information that we have
- 1:42:51available to us. But still, again, a lot of work to be done.
- 1:42:57You know, you don't, you're not gonna really know that until you
- 1:43:00do the trials.
- 1:43:02Okay, this has been excellent two part, two part interview.
- 1:43:06Before we close out, and I get sort of whatever final
- 1:43:10information you want to share us with, what's, what's next for
- 1:43:13you? What are you working on now? Like, what has you excited as a
- 1:43:17scientist right now?
- 1:43:18Okay, yeah, yes, we're developing. We're working on a
- 1:43:23drug delivery system with a guy who kind of invented this in
- 1:43:26radiology here at Stanford, Rage, Iran. It's this idea of
- 1:43:29that we can package drug and nanoparticles, and use ultrasound
- 1:43:33to release it into specific brain regions and deliver drug just
- 1:43:37to that brain region. So it'll help us to understand kind of
- 1:43:40brain behavior relationships.
- 1:43:42Cool. And, and what's, what's next for, for people who are
- 1:43:48interested in your, your stuff with Ibogaine here? Should they
- 1:43:53be waiting expecting follow up reports at any time or follow up
- 1:43:56papers?
- 1:43:57Yeah, we have a ton of papers coming out on the neuroimaging in
- 1:43:59the EEG and the long term follow up and then looking into other
- 1:44:02ways to do this in the US. So a lot of Ibogaine work, you know, is
- 1:44:07coming that paper was just the first one. Yeah, excellent. So
- 1:44:11obviously, you're a scientist, not a social media influencer.
- 1:44:14But if you have any sort of social media channels or
- 1:44:18somewhere that you would suggest people that they would follow
- 1:44:21you to stay up to date on your research, or, or, or, or, or
- 1:44:26or, or you know, get in contact with you in some way. Yeah, the
- 1:44:31X, Twitter, whatever, handles Nolan, RY, Williams. And, and
- 1:44:39so people can see me there, Nolan R Williams.com is the website.
- 1:44:44Happy for anybody to kind of check in with us around studies
- 1:44:49and papers and all that good stuff. So thank you, sir.
- 1:44:52Appreciate the time.
- 1:44:53Thank you so much, Dr. Nolan Williams, been a excellent
- 1:44:56conversation, and I appreciate you offering your time today.
- 1:45:00Thanks, man. Take it easy. Goodbye.
- 1:45:03Okay, thank you so much for tuning into this episode,
- 1:45:06listening all the way to the end. If you're like me, you're
- 1:45:09probably really excited about the work that Dr. Williams is
- 1:45:13achieving here with Ibogaine with traumatic brain injury in
- 1:45:17connection with MBO. And you want to really stay up to date
- 1:45:22with what's coming out with respect to that. And so
- 1:45:25definitely follow Dr. Williams at his X handle, the platform
- 1:45:31formerly known as Twitter. And in order to, in order to stay up
- 1:45:37to date with what he's doing, if you'd like to stay up to date
- 1:45:39with what I'm doing, you become, you could become a free member
- 1:45:42of Patreon to follow my posts there, or you could become a
- 1:45:46pledged member of Patreon, which would help contribute to the
- 1:45:50resources that are required to produce the show both time and
- 1:45:54material. Or you could sign up for my newsletter, I send a
- 1:45:59newsletter once a month or so. Or you could follow my, my
- 1:46:05telegram. Links to all of that are in the description to this
- 1:46:08episode, wherever you're checking out. I appreciate that
- 1:46:10very much. If you're interested in psychedelic mushrooms, I have
- 1:46:14a couple of books that I've written on them. I'm in
- 1:46:17production on the third. My second book, it's a storytelling
- 1:46:20narrative, the true light of darkness, my first one, more
- 1:46:23academic scholarly style, decomposing the shadow, both of
- 1:46:28which are available on Amazon, or, you know, somewhere that
- 1:46:33isn't Amazon if supporting Jeff Bezos is not your highest
- 1:46:36highest desire. And they're also available at ebook, or you could
- 1:46:39get signed copies from me directly from my site. And yeah,
- 1:46:44that's it for this episode. Thank you so much for tuning in
- 1:46:47all the way to the end. And until the next one, take care.